Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market May 18, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
